The nomenclature change from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) marks a significant advancement in liver disease understanding as it recognizes the role of metabolic factors beyond fat accumulation in liver disease. The webinar will delve into the rationale and purpose of this shift in nomenclature in its ability to foster interdisciplinary collaboration, enhance public health initiatives, and drive focused research in the various phenotypes within steatotic liver diseases for improved patient outcomes. Embracing MASLD heralds a future of effective liver disease management including pharmacologic and non-pharmacologic intervention(s) and empowers healthcare professionals to better understand and manage the disease.

Our audience will gain a better understanding of the rationale behind the nomenclature change in steatotic liver disease classification, specifically on the evolving evidence and concepts in liver disease pathophysiology that necessitated the shift in nomenclature. Emphasis will be placed on the clinical application of the new classification, exploring how it enables more accurate diagnoses and tailored interventions for patients. Lastly, its potential implications for future research and pharmacologic development, showcasing its role in advancing the field and improving patient outcomes.